Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.67 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.67 |
| ▸ | NR1I2 | O75469 | 10/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13955500 | 1.00 | KCNH2 (0.67) | KCNH2CYP3A4SCN5ANR1I2CYP2C9 | |
| SCHEMBL12034515 | 1.00 | KCNH2 (0.67) | KCNH2CYP3A4SCN5ANR1I2CYP2C9 | |
| SCHEMBL14081119 | 0.89 | NR1I2 (0.68) | KCNH2CYP3A4SCN5ANR1I2CYP2C9 | |
| SCHEMBL12809541 | 0.88 | KCNH2 (0.52) | KCNH2CYP3A4SCN5ANR1I2CYP2C9 | |
| SCHEMBL13188144 | 0.87 | KCNH2 (0.67) | KCNH2CYP3A4SCN5ANR1I2CYP2C9 | |
| SCHEMBL14369960 | 0.87 | NR1I2 (0.67) | KCNH2CYP3A4SCN5ANR1I2CYP2C9 | |
| SCHEMBL2637665 | 0.84 | NR1I2 (0.64) | KCNH2CYP3A4SCN5ANR1I2CYP2C9 | |
| SCHEMBL13356046 | 0.84 | NR1I2 (0.76) | KCNH2CYP3A4SCN5ANR1I2CYP2C9 | |
| SCHEMBL3893256 | 0.84 | NR1I2 (0.61) | KCNH2CYP3A4SCN5ANR1I2CYP2C9 | |
| SCHEMBL14253915 | 0.84 | NR1I2 (0.63) | KCNH2CYP3A4SCN5ANR1I2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556204-B2 | Methods and intermediates for the preparation of (4bS,5aR)-12-cyclohexyl-N-(N,N-dimethylsulfamoyl)-3-methoxy-5a-((1R,5S)-3-methyl-3,8-diazabicyclo [3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-A]indole-9-carboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-01-31 | — | — | US | disclosed |
| US-20150133654-A1 | NOVEL METHODS AND INTERMEDIATES FOR THE PREPARATION OF (4bS,5aR)-12-CYCLOHEXYL-N-(N,N-DIMETHYLSULFAMOYL)-3-METHOXY-5a-((1R,5S)-3-METHYL-3,8-DIAZABICYCLO[3.2.1]OCTANE-8-CARBONYL)-4b,5,5a,6-TETRAHYDROBENZO [3,4]CYCLOPROPA[5,6]AZEPINO[1,2-A]INDOLE-9-CARBOXAMIDE | BRISTOL-MYERS SQUIBB COMPANY | 2015-05-14 | — | — | US | disclosed |
| WO-2008112473-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2007136982-A1 | CYCLOPROPYL FUSED INDOLOBENZAZEPINE HCV NS5B INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133654-A1 | NOVEL METHODS AND INTERMEDIATES FOR THE PREPARATION OF (4bS,5aR)-12-CYCLOHEXYL-N-(N,N-DIMETHYLSULFAMOYL)-3-METHOXY-5a-((1R,5S)-3-METHYL-3,8-DIAZABICYCLO[3.2.1]OCTANE-8-CARBONYL)-4b,5,5a,6-TETRAHYDROBENZO [3,4]CYCLOPROPA[5,6]AZEPINO[1,2-A]INDOLE-9-CARBOXAMIDE | HTR3C, HTR2C, HTR1B | KCNH2 200/4885CYP3A4 46/4885SCN5A 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.